Which has higher earnings and valuation, AURA or OKUR?

Aura Biosciences is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aura Biosciences N/A N/A -$106.19M -$1.74 N/A OnKure Therapeutics N/A N/A -$59.52M -$4.33 N/A

Is AURA or OKUR more profitable?

OnKure Therapeutics' return on equity of -61.02% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -78.12% -64.08% OnKure Therapeutics N/A -61.02% -55.99%

Does the media refer more to AURA or OKUR?

In the previous week, OnKure Therapeutics had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 2 mentions for OnKure Therapeutics and 1 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.97 beat OnKure Therapeutics' score of 0.00 indicating that Aura Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive OnKure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, OKUR or EIKN?

Eikon Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OnKure Therapeutics N/A N/A -$59.52M -$4.33 N/A Eikon Therapeutics N/A N/A N/A -$2.46 N/A

Is OKUR or EIKN more profitable?

Eikon Therapeutics' return on equity of 0.00% beat OnKure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets OnKure Therapeutics N/A -61.02% -55.99% Eikon Therapeutics N/A N/A N/A

Does the media prefer OKUR or EIKN?

In the previous week, OnKure Therapeutics had 1 more articles in the media than Eikon Therapeutics. MarketBeat recorded 2 mentions for OnKure Therapeutics and 1 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 1.86 beat OnKure Therapeutics' score of 0.00 indicating that Eikon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OnKure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eikon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor OKUR or ACRS?

In the previous week, OnKure Therapeutics had 1 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 2 mentions for OnKure Therapeutics and 1 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.50 beat OnKure Therapeutics' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OnKure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aclaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OKUR or FDMT?

In the previous week, 4D Molecular Therapeutics had 7 more articles in the media than OnKure Therapeutics. MarketBeat recorded 9 mentions for 4D Molecular Therapeutics and 2 mentions for OnKure Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.36 beat OnKure Therapeutics' score of 0.00 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OnKure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral 4D Molecular Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

OnKure Therapeutics (OKUR) Competitors

$4.58 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$4.58 +0.00 (+0.11%)

As of 07/2/2026 04:10 PM Eastern

Compare

OKUR vs. GYRE, AURA, EIKN, ACRS, and FDMT

Should you buy OnKure Therapeutics stock or one of its competitors? MarketBeat compares OnKure Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with OnKure Therapeutics include Gyre Therapeutics (GYRE), Aura Biosciences (AURA), Eikon Therapeutics (EIKN), Aclaris Therapeutics (ACRS), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "pharmaceutical products" industry.

How does OnKure Therapeutics compare to Gyre Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

Gyre Therapeutics has higher revenue and earnings than OnKure Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A
Gyre Therapeutics	$117.05M	6.99	$5.03M	-$0.09	N/A

OnKure Therapeutics has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-61.02%	-55.99%
Gyre Therapeutics	-5.44%	3.13%	2.67%

91.0% of OnKure Therapeutics shares are held by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are held by institutional investors. 2.3% of OnKure Therapeutics shares are held by company insiders. Comparatively, 9.5% of Gyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, OnKure Therapeutics had 2 more articles in the media than Gyre Therapeutics. MarketBeat recorded 2 mentions for OnKure Therapeutics and 0 mentions for Gyre Therapeutics. OnKure Therapeutics' average media sentiment score of 0.00 equaled Gyre Therapeutics'average media sentiment score.

Company	Overall Sentiment
OnKure Therapeutics	Neutral
Gyre Therapeutics	Neutral

OnKure Therapeutics presently has a consensus price target of $27.00, indicating a potential upside of 489.52%. Gyre Therapeutics has a consensus price target of $17.00, indicating a potential upside of 131.61%. Given OnKure Therapeutics' higher possible upside, equities analysts clearly believe OnKure Therapeutics is more favorable than Gyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

OnKure Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market.

Summary

Gyre Therapeutics beats OnKure Therapeutics on 8 of the 13 factors compared between the two stocks.

How does OnKure Therapeutics compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Aura Biosciences is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A

Aura Biosciences presently has a consensus target price of $20.50, indicating a potential upside of 164.86%. OnKure Therapeutics has a consensus target price of $27.00, indicating a potential upside of 489.52%. Given OnKure Therapeutics' higher probable upside, analysts plainly believe OnKure Therapeutics is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

OnKure Therapeutics' return on equity of -61.02% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
OnKure Therapeutics	N/A	-61.02%	-55.99%

In the previous week, OnKure Therapeutics had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 2 mentions for OnKure Therapeutics and 1 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.97 beat OnKure Therapeutics' score of 0.00 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
OnKure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are owned by institutional investors. 1.9% of Aura Biosciences shares are owned by insiders. Comparatively, 2.3% of OnKure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Aura Biosciences has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

Summary

OnKure Therapeutics beats Aura Biosciences on 7 of the 13 factors compared between the two stocks.

How does OnKure Therapeutics compare to Eikon Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and Eikon Therapeutics (NASDAQ:EIKN) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

OnKure Therapeutics presently has a consensus target price of $27.00, indicating a potential upside of 489.52%. Eikon Therapeutics has a consensus target price of $25.20, indicating a potential upside of 100.96%. Given OnKure Therapeutics' higher probable upside, equities research analysts plainly believe OnKure Therapeutics is more favorable than Eikon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

Eikon Therapeutics' return on equity of 0.00% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-61.02%	-55.99%
Eikon Therapeutics	N/A	N/A	N/A

91.0% of OnKure Therapeutics shares are held by institutional investors. 2.3% of OnKure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, OnKure Therapeutics had 1 more articles in the media than Eikon Therapeutics. MarketBeat recorded 2 mentions for OnKure Therapeutics and 1 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 1.86 beat OnKure Therapeutics' score of 0.00 indicating that Eikon Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OnKure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eikon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Eikon Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A
Eikon Therapeutics	N/A	N/A	N/A	-$2.46	N/A

Summary

Eikon Therapeutics beats OnKure Therapeutics on 6 of the 11 factors compared between the two stocks.

How does OnKure Therapeutics compare to Aclaris Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

OnKure Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

OnKure Therapeutics has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Aclaris Therapeutics' return on equity of -55.89% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-61.02%	-55.99%
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

In the previous week, OnKure Therapeutics had 1 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 2 mentions for OnKure Therapeutics and 1 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.50 beat OnKure Therapeutics' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OnKure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 2.3% of OnKure Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

OnKure Therapeutics has higher earnings, but lower revenue than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A
Aclaris Therapeutics	$8.37M	92.81	-$64.92M	-$0.56	N/A

OnKure Therapeutics currently has a consensus price target of $27.00, suggesting a potential upside of 489.52%. Aclaris Therapeutics has a consensus price target of $11.50, suggesting a potential upside of 106.83%. Given OnKure Therapeutics' higher probable upside, research analysts plainly believe OnKure Therapeutics is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Summary

Aclaris Therapeutics beats OnKure Therapeutics on 11 of the 16 factors compared between the two stocks.

How does OnKure Therapeutics compare to 4D Molecular Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

91.0% of OnKure Therapeutics shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 2.3% of OnKure Therapeutics shares are held by insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

OnKure Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.7, indicating that its share price is 170% more volatile than the broader market.

OnKure Therapeutics has higher earnings, but lower revenue than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A
4D Molecular Therapeutics	$85.21M	7.98	-$140.11M	-$2.57	N/A

OnKure Therapeutics currently has a consensus price target of $27.00, indicating a potential upside of 489.52%. 4D Molecular Therapeutics has a consensus price target of $29.88, indicating a potential upside of 129.81%. Given OnKure Therapeutics' higher probable upside, analysts plainly believe OnKure Therapeutics is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

OnKure Therapeutics has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. 4D Molecular Therapeutics' return on equity of -36.83% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-61.02%	-55.99%
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%

In the previous week, 4D Molecular Therapeutics had 7 more articles in the media than OnKure Therapeutics. MarketBeat recorded 9 mentions for 4D Molecular Therapeutics and 2 mentions for OnKure Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.36 beat OnKure Therapeutics' score of 0.00 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OnKure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
4D Molecular Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

4D Molecular Therapeutics beats OnKure Therapeutics on 11 of the 15 factors compared between the two stocks.

Get OnKure Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OKUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OKUR vs. The Competition

Export

Metric	OnKure Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$185.01M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-1.06	21.61	28.02	24.70
Price / Sales	N/A	340.19	540.37	99.49
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	1.11	8.66	10.96	6.46
Net Income	-$59.52M	$23.81M	$3.57B	$337.01M
7 Day Performance	1.78%	3.39%	2.12%	1.69%
1 Month Performance	9.31%	10.81%	5.25%	3.81%
1 Year Performance	90.83%	62.61%	33.29%	23.90%

OnKure Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OKUR OnKure Therapeutics	2.141 of 5 stars	$4.58 flat	$27.00 +489.5%	+90.8%	$185.01M	N/A	N/A	N/A	News Coverage
GYRE Gyre Therapeutics	1.7971 of 5 stars	$6.59 +2.2%	$17.00 +158.0%	-9.8%	$719.10M	$116.59M	N/A	40	News Coverage Positive News
AURA Aura Biosciences	2.2934 of 5 stars	$7.10 +3.2%	$20.50 +188.7%	+17.5%	$711.30M	N/A	N/A	50	Positive News Gap Down High Trading Volume
EIKN Eikon Therapeutics	2.3788 of 5 stars	$13.05 +2.4%	$25.20 +93.1%	N/A	$706.51M	N/A	N/A	384	Positive News
ACRS Aclaris Therapeutics	3.179 of 5 stars	$5.29 +5.4%	$11.50 +117.4%	+284.8%	$701.11M	$7.83M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OKUR) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OnKure Therapeutics (OKUR) Competitors

OKUR vs. GYRE, AURA, EIKN, ACRS, and FDMT

How does OnKure Therapeutics compare to Gyre Therapeutics?

Summary

How does OnKure Therapeutics compare to Aura Biosciences?

Summary

How does OnKure Therapeutics compare to Eikon Therapeutics?

Summary

How does OnKure Therapeutics compare to Aclaris Therapeutics?

Summary

How does OnKure Therapeutics compare to 4D Molecular Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR vs. The Competition

OnKure Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OnKure Therapeutics (OKUR) Competitors

OKUR vs. GYRE, AURA, EIKN, ACRS, and FDMT

How does OnKure Therapeutics compare to Gyre Therapeutics?

Which has stronger valuation and earnings, OKUR or GYRE?

Is OKUR or GYRE more profitable?

Do institutionals & insiders have more ownership in OKUR or GYRE?

Does the media favor OKUR or GYRE?

Do analysts rate OKUR or GYRE?

Which has more volatility and risk, OKUR or GYRE?

Summary

How does OnKure Therapeutics compare to Aura Biosciences?

Which has higher earnings and valuation, AURA or OKUR?

Do analysts recommend AURA or OKUR?

Is AURA or OKUR more profitable?

Does the media refer more to AURA or OKUR?

Do insiders & institutionals have more ownership in AURA or OKUR?

Which has more volatility and risk, AURA or OKUR?

Summary

How does OnKure Therapeutics compare to Eikon Therapeutics?

Do analysts prefer OKUR or EIKN?

Is OKUR or EIKN more profitable?

Do insiders and institutionals believe in OKUR or EIKN?

Does the media prefer OKUR or EIKN?

Which has better valuation and earnings, OKUR or EIKN?

Summary

How does OnKure Therapeutics compare to Aclaris Therapeutics?

Which has more risk and volatility, OKUR or ACRS?

Is OKUR or ACRS more profitable?

Does the media favor OKUR or ACRS?

Do institutionals and insiders hold more shares of OKUR or ACRS?

Which has preferable earnings and valuation, OKUR or ACRS?

Do analysts prefer OKUR or ACRS?

Summary

How does OnKure Therapeutics compare to 4D Molecular Therapeutics?

Do institutionals & insiders believe in OKUR or FDMT?

Which has more volatility & risk, OKUR or FDMT?

Which has better earnings and valuation, OKUR or FDMT?

Do analysts prefer OKUR or FDMT?

Is OKUR or FDMT more profitable?

Does the media favor OKUR or FDMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR vs. The Competition

OnKure Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools